Game Changing Allogeneic Cell Therapy for Tissue Repair
2 major innovations in allogeneic cell therapy
• Innovative bioproduction using non-modified human GFs decreases production costs to allow greater patient access to effective allogeneic cell therapy
•A unique combination of anti-inflammatory and tissue repair properties via immune tolerance may allow for new treatments to be created for many diseases, such as inflammatory and tissue repair disorders.
• Scarcell Therapeutics' goal is to provide an effective new regenerative therapy at a lower cost
• Environmentally friendly bioproduction process
• May reduce drug consumption
Scarcell therapeutics collaborates with a network of renowned partners and institutional bodies
The production process is developed in partnership with CDMOs
Scarcell Therapeutics is supported by the following clusters and Bpifrance.
Scarcell Therapeutics is privately funded and has been granted non-dilutive funding from the French government (France 2030) and the European Union (Next Generation EU).